Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.

Dapagliflozin + saxagliptin + metformin combo may reduce HbA1c in T2D

Elaine Soliven
22 Sep 2017

Adding dapagliflozin and saxagliptin to metformin may reduce HbA1c levels in patients with uncontrolled type 2 diabetes (T2D), according to a study presented at EASD 2017.

Four hundred and sixty one patients (mean age 55.9 years, 45.6 percent male, mean body mass index 33.1 kg/m2) with T2D for 8 years (mean HbA1c 8.8 percent) were randomized to triple therapy (n=232, dapagliflozin [10 mg/day] + saxagliptin [5 mg/day] + metformin [≥1,500 mg/day]) or dual therapy (n=229, sitagliptin [100 mg/day] + metformin) for 26 weeks. [EASD 2017, abstract 40]

A significant reduction in HbA1c level was noted in patients treated with triple therapy compared with dual therapy (-1.41 percent vs -1.07 percent) at 26 weeks.

The benefit of triple vs dual therapy in HbA1c reduction was evident regardless of patient’s age (-1.4 percent vs -1.0 percent [age <65 years] and -1.4 percent vs -1.3 percent [age ≥65 years]) or gender (-1.4 percent vs -1.2 percent [males] and -1.4 percent vs -1.0 percent [females]).

In addition, bigger reductions in total body weight and fasting plasma glucose were noted at 26 weeks in patients who received triple therapy than dual therapy (-1.9 vs -0.5 kg and -32 vs -11 mg/dL, respectively).

At 26 weeks, more patients on triple therapy than dual therapy achieved HbA1c <7 percent (37 percent vs 25 percent).

Urinary tract infections were more frequent in patients on triple therapy compared with dual therapy (4.7 percent vs 2.2 percent).

“Improvements in HbA1c with [the] addition of once daily dapagliflozin + saxagliptin [to] metformin were greater than with [the] addition of sitagliptin alone and were achieved regardless of [the patient’s] baseline HbA1c, age, sex, race, and region,” said lead author Professor Stefano Del Prato from the University of Pisa School of Medicine and Chief of the Section of Diabetes at the University of Pisa, Italy.

Overall, triple therapy was well tolerated, and no patient experienced a major episode of hypoglycaemia, Del Prato added.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 4 days ago

The combined use of piperacillin and tazobactam does not appear to be a suitable alternative to meropenem for patients with bloodstream infections caused by ceftriaxone-resistant Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pneumoniae), according to results of the MERINO* trial.

Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
2 days ago
Patients with inflammatory bowel disease are at increased risk of developing acute myocardial infarction (AMI) or heart failure, although the prevalence of traditional risk factors for such cardiovascular disorders appears to be low, as reported in a recent study.
3 days ago
Early renin-angiotensin-aldosterone system (RAAS) blockade with renin-angiotensin system inhibitors (RASI) leads to better short- and long-term renal outcomes in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study, adding that this renal protective effect is independent of RASI’s antihypertensive and antiproteinuric effects.